Pipeline

NKMax is conducting numerous clinical trials to discover how natural killer (NK) cells can help patients with cancer and neurodegenerative conditions.

SNK01, NKMax’s first cell therapy candidate, has planned clinical trials in several therapeutic areas, including oncology and neurodegeneration. This approach allows us to evaluate the potential benefits of adoptive cellular immunotherapy for multiple biologically relevant disease areas.

Product

Discovery

Preclinical

Phase I

Phase II

Phase III

SNK01


– Refractory Solid Tumors, Phase l
– Stage I-III Triple Negative Breast Cancer*, Phase l
– Localized/ Metastatic Sarcoma*, Phase l
– Immune Related Diseases, Preclinical

Refractory Solid Tumors
Stage I-III Triple Negative Breast Cancer1
Localized/ Metastatic Sarcoma1
Immune Related Diseases

SNK01 +

pembrolizumab


– Stage IV Non- Small Cell Lung Cancer, Phase ll
– Refractory PD-L1+ and PD-L1- Solid Tumors**, Phase ll

Stage IV Non- Small Cell Lung Cancer
Refractory PD-L1+ and PD-L1- Solid Tumors 2

SNK01 +

trastuzumab or cetuximab

Refractory HER2+ or EGFR+ Solid Tumors***, Phase l

Allogeneic SNK

Not Disclosed

CAR-SNK

Not Disclosed

Refractory HER2+ or EGFR+ Solid Tumors 3
Not Disclosed
Not Disclosed

1 Following the completion of our Phase 1 trial, we intend to initiate Phase 2 clinical trials in stage I-III triple negative breast cancer and localized/metastatic sarcoma.
2 Following the completion of our Phase 1/2 trial, we intend to initiate a Phase 2 clinical trial in refractory PD-L1+ and PD-L1- solid tumors with SNK in combination with pembrolizumab.
3 Following the completion of our Phase 1 trial, we intend to initiate a Phase 1 clinical trial in refractory HER2+ or EGFR+ solid tumors with SNK in combination with trastuzumab or cetuximab.